View Older Stories View More Recent Stories

Jul 17, 2018 04:05PM Exelixis to Release Second Quarter 2018 Financial Results on Wednesday, August 1, 2018
Jul 5, 2018 06:05AM Exelixis (EXEL) Reports CELESTIAL Phase 3 Pivotal Trial Results Published in The New England Journal of Medicine
Jul 4, 2018 05:00PM Exelixis Announces CELESTIAL Phase 3 Pivotal Trial Results Published in The New England Journal of Medicine
Jun 27, 2018 08:00AM Exelixis to Be Added to the S&P MidCap 400 Index
Jun 5, 2018 04:05PM Exelixis to Present at the William Blair & Co. 38th Annual Growth Stock Conference on June 12, 2018
Jun 4, 2018 06:47AM Exelixis (EXEL) Updates Results from Sub-Group Analyses of the Phase 3 Pivotal CELESTIAL Trial of Cabozantinib for Advanced Hepatocellular Carcinoma
Jun 3, 2018 09:00AM Exelixis Announces Results from Sub-Group Analyses of the Phase 3 Pivotal CELESTIAL Trial of Cabozantinib for Advanced Hepatocellular Carcinoma Presented at ASCO 2018
Jun 1, 2018 08:02AM Exelixis (EXEL) Reports Further Expansion to Clinical Research Protocol for Phase 1b COSMIC-021 Trial of Cabozantinib in Combination with Anti-PD-L1 Immunotherapy
Jun 1, 2018 08:00AM Exelixis Announces Further Expansion to Clinical Research Protocol for Phase 1b COSMIC-021 Trial of Cabozantinib in Combination with Anti-PD-L1 Immunotherapy in Patients with Locally Advanced or Metas
May 29, 2018 04:11PM Exelixis (EXEL) Announces U.S. FDA Accepts sNDA for CABOMETYX in Previously Treated Advanced Hepatocellular Carcinoma
May 29, 2018 04:05PM Exelixis Announces U.S. FDA Accepts Supplemental New Drug Application for CABOMETYX® (cabozantinib) in Previously Treated Advanced Hepatocellular Carcinoma
May 22, 2018 04:15PM Exelixis Appoints Andrew R. Peters to Newly Created Position of Vice President, Strategy
May 17, 2018 05:59AM Exelixis (EXEL) Partner Ipsen Reports European Commission Approval of CABOMETYX (Cabozantinib)
May 17, 2018 01:01AM Exelixis’ Partner Ipsen Announces European Commission Approval of CABOMETYX® (Cabozantinib) for Previously Untreated Intermediate- or Poor-Risk Advanced Renal Cell Carcinoma
May 10, 2018 05:46AM Exelixis (EXEL) Reports Update on IMblaze370 Phase 3 Pivotal Trial of Atezolizumab and Cobimetinib
May 10, 2018 01:01AM Exelixis Provides Update on IMblaze370 Phase 3 Pivotal Trial of Atezolizumab and Cobimetinib in Patients With Heavily Pretreated Locally Advanced or Metastatic Colorectal Cancer
May 8, 2018 04:05PM Exelixis to Present at the Bank of America Merrill Lynch Health Care Conference on May 15, 2018
May 2, 2018 04:06PM Exelixis and Invenra Enter Into Collaboration to Discover and Develop Novel Biologics to Treat Cancer
May 2, 2018 04:05PM Exelixis Announces First Quarter 2018 Financial Results and Provides Corporate Update
Apr 26, 2018 08:00AM Cabozantinib to Be Featured in 15 Presentations at ASCO 2018 Annual Meeting
Apr 11, 2018 04:05PM Exelixis to Release First Quarter 2018 Financial Results on Wednesday, May 2, 2018
Apr 9, 2018 04:07PM Exelixis (EXEL) Announces Election of Dr. Maria Freire to Board
Apr 9, 2018 04:05PM Exelixis Elects Dr. Maria Freire to Its Board of Directors
Mar 28, 2018 05:50AM Exelixis (EXEL) Partner Ipsen Reports EMA Validation of Application for New Indication for CABOMETYX (cabozantinib)
Mar 28, 2018 01:05AM Exelixis’ Partner Ipsen Announces EMA Validation of the Application for a New Indication for CABOMETYX® (cabozantinib) for Previously Treated Advanced Hepatocellular Carcinoma
Mar 23, 2018 06:04AM Exelixis (EXEL) Reports Positive CHMP Opinion for CABOMETYX (cabozantinib)
Mar 23, 2018 02:05AM Exelixis’ Partner Ipsen Announces Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Previously Untreated Intermediate- or Poor-Risk Advanced Renal Cell Carcinoma
Mar 15, 2018 08:02AM Exelixis (EXEL) Submits sNDA for CABOMETYX for Previously Treated Advanced Hepatocellular Carcinoma
Mar 15, 2018 08:00AM Exelixis Submits U.S. Supplemental New Drug Application for CABOMETYX® (Cabozantinib) for Previously Treated Advanced Hepatocellular Carcinoma
Mar 6, 2018 04:05PM Exelixis Announces Webcasts of Investor Conference Presentations in March
Feb 26, 2018 08:00PM Exelixis Announces Collaborator Daiichi Sankyo’s Submission of Regulatory Filing for Esaxerenone (CS-3150) in Japan
Feb 26, 2018 04:05PM Exelixis Announces Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update
Feb 14, 2018 04:05PM Exelixis to Present at the RBC Capital Markets Global Healthcare Conference on February 21, 2018
Feb 13, 2018 04:10PM Exelixis (EXEL) Announces Results from Phase 2 Trial of Cabozantinib in First-Line Treatment of Metastatic Radioiodine-Refractory DTC
Feb 13, 2018 04:05PM Exelixis Announces Results from a Phase 2 Investigator-Sponsored Trial of Cabozantinib in the First-Line Treatment of Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma
Feb 8, 2018 04:05PM Exelixis to Release Fourth Quarter and Full Year 2017 Financial Results on Monday, February 26, 2018
Feb 7, 2018 08:04AM Exelixis (EXEL) Announces Updated Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab with or without Ipilimumab in Refractory GU Tumors
Feb 7, 2018 08:00AM Exelixis Announces Updated Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab with or without Ipilimumab in Refractory Genitourinary (GU) Tumors
Feb 6, 2018 04:05PM Exelixis to Present at the Leerink Partners Global Healthcare Conference on February 14
Jan 22, 2018 05:47AM Exelixis (EXEL) Announced Updated Phase 1b Results for Combination of Cobimetinib and Atezolizumab in Metastatic Colorectal Cancer at ASCO 2018
Jan 20, 2018 10:55AM Exelixis Announces Presentation of Updated Phase 1b Results for the Combination of Cobimetinib and Atezolizumab in Metastatic Colorectal Cancer at the 2018 American Society of Clinical Oncology Gastro
Jan 16, 2018 05:02PM Exelixis (EXEL), Ipsen Report Phase 3 Trial Results of Cabozantinib Demonstrating Significant OS Benefit in Patients with Previously Treated Advanced Hepatocellular Carcinoma
Jan 16, 2018 05:01PM Exelixis and Ipsen Announce Phase 3 Trial Results of Cabozantinib Demonstrating Significant Overall Survival Benefit in Patients with Previously Treated Advanced Hepatocellular Carcinoma
Jan 9, 2018 08:00AM Exelixis to Co-Host Financial Community Briefing to Discuss Data Presented at the 2018 American Society of Clinical Oncology Gastrointestinal Cancers Symposium
Jan 8, 2018 08:08AM Exelixis (EXEL) And StemSynergy Enter into Pact for Discovery and Development of Novel Anticancer Therapies
Jan 8, 2018 08:00AM Exelixis and StemSynergy Enter into Exclusive Licensing Agreement for the Discovery and Development of Novel Anticancer Therapies
Jan 4, 2018 08:05AM Exelixis (EXEL) Amends Research Protocol for Phase 1b Trial of Cabozantinib in Combination with Atezolizumab in Patients with Locally Advanced or Metastatic Solid Tumors
Jan 4, 2018 08:00AM Exelixis Announces Amendment to Clinical Research Protocol for Phase 1b Trial of Cabozantinib in Combination with Atezolizumab in Patients with Locally Advanced or Metastatic Solid Tumors
Dec 19, 2017 02:59PM Exelixis (EXEL) Confirms FDA Approval of CABOMETYX Tablets for Previously Untreated Advanced RCC
Dec 19, 2017 02:54PM Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) Tablets for Previously Untreated Advanced Renal Cell Carcinoma
View More Recent Stories View Older Stories